Cord Blood Stem Cells

Cord blood is the excess blood found in the placenta and umbilical cord after your baby is born. It is rich in hematopoietic stem cells (HSCs) that produce blood tissue in the human body.

If not collected at the time of your baby’s birth, this precious resource will be discarded as medical waste. Learn more about cord blood.

Stem cells from cord blood are the “building blocks” of our blood and immune systems. They are capable of self-renewal and regeneration and have the amazing ability to repair and rebuild damaged tissue within the body.

More than 80 diseases and conditions are FDA-approved for treatment with cord blood stem cells, including leukemia, lymphoma, various anemias and more.

In addition to the 80+ FDA-approved treatments, more than 3,500 clinical trials have been initiated exploring new therapies using cord blood stem cells.

Research in regenerative medicine has shown potential to treat diabetes, cerebral palsy, autism, spinal cord injuries and heart disease.

It is estimated that as many as 1 in 3 people in the United States may benefit from stem cell regenerative medicine therapy, including treatments for type 1 diabetes, multiple sclerosis, stroke, heart failure, liver damage, Alzheimer’s, and more.

1 Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4:269-274. Epub August 5, 2008.

Yes. The following have been approved by the FDA for autologous transplant (treating the child with their own stem cells): 

  • Hodgkin’s Lymphoma
  • Aplastic Anemia
  • Multiple Myeloma
  • Plasma Cell Leukemia
  • Waldenstrom’s Macroglobulinemia
  • Neuroblastoma
  • Medulloblastoma
  • Retinoblastoma
  • Amyloidosis and Testicular Cancer (germ cell tumors)

In addition, many clinical trials have been initiated using a patient’s own cord blood stem cells, including:

  • Autism
  • Cerebral Palsy
  • Ischemic Stroke
  • Type 1 Diabetes
  • Global Developmental Delay
  • Traumatic Brain Injury

There are, however, some conditions for which doctors will prefer to use stem cells from a related donor such as a sibling or child. As such, it is recommended that you bank cord blood for each of your children.

1. Parent’s Guide to Cord Blood Foundation. Retrieved February 10, 2025. Diseases that can be Treated with Cord Blood. https://parentsguidecordblood.org/en/diseases

Yes. Scientists have developed a method to expand the number of stem cells within a cord blood unit before infusing them into adult patients.

Expanded cord blood units result in up to a 164-fold increase in the number of hematopoietic stem cells, making one cord blood unit suitable for transplant in an average size adult.

1 Fred Hutchinson Cancer Research Center (2010, January 18). First successful use of expanded umbilical- cord blood
units to treat leukemia. Science Daily. Retrieved January 20, 2010, from http://www.sciencedaily.com/releases/2010/01/100117150820.htm? utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+ News%29

HLA, or human leukocyte antigens, are the proteins that control tissue compatibility. The closer the match, the less risk of a potentially fatal condition called GVHD, or graft-versus-host disease (also known as “rejection”).

There is no risk of GVHD when a child receives his or her own cord blood. Within a family, there is a high probability of cord blood matching a sibling or parent, thereby significantly reducing the risk of GVHD.

Outside of the family, the situation is much different. HLA antigens are highly polymorphic, with hundreds of different HLA antigens found in the human population (roughly 750,000 possible combinations of three HLA antigens alone).

Your best chance of providing a match for your family is to bank your baby’s own cord blood.

1 Beatty, P., & Dahlberg, S. (1988). Probability of finding HLA-matched unrelated marrow donors. Transplantation (4), 714-718.

GVHD, or graft-versus-host disease, is the leading cause of death following transplant surgery. Nearly 50% of all patients who develop GVHD will die as a result.

GVHD occurs when the healthy cells of the donor tissue attack the immunocompromised cells of the recipient.

The risk of GVHD is directly related to tissue compatibility and the biological relationship of the donor to the recipient, which is described in terms of HLA matching.

Siblings and parents of the child that the stem cells came from will have the greatest chance of a perfect or close HLA match. The closer the HLA match, the lower your risk of GVHD.

1 eMedicine. (January 6, 2009). Retrieved April 1, 2010 from Graft Versus Host Disease: Mortality/Morbidity: http://emedicine.medscape.com/article/886758-overview.

Yes. The risk and severity of GVHD is much higher with stem cells from bone marrow than it is with stem cells derived from cord blood and cord tissue.

In addition, cells from bone marrow are more likely to have been exposed to latent diseases and DNA degradation.

Yes. Cord blood stem cells are distinctively different from embryonic stem cells.

Cord blood stem cells are collected from the umbilical cord after your baby is born, and if not saved are discarded as medical waste. There are no ethical oppositions to the use of cord blood stem cells.

Embryonic stem cells are derived from a process that inhibits the life of the embryo, which make them highly controversial.

No. After more than three decades and greater than 45,000 cord blood transplants worldwide, the use of cord blood stem cells is FDA-approved in the treatment of more than 80 diseases and conditions.1,2

1. National Library of Medicine: National Center for Biotechnology Information. Retrieved February 10, 2025. Cord blood 2.0: state of the art and future directions in transplant medicine. https://pmc.ncbi.nlm.nih.gov/articles/PMC6439299/
2. Parent’s Guide to Cord Blood Foundation. Retrieved February 10, 2025. Diseases that can be Treated with Cord Blood. https://parentsguidecordblood.org/en/diseases

The field of stem cell therapy is growing rapidly, and the future potential is unlimited.

There are more than 3,500 clinical trials initiated evaluating the use of cord blood stem cells to treat diabetes, cerebral palsy, autism, spinal cord injuries, heart disease, and many more. Scientists are also using cord blood stem cells to stimulate lung development in premature babies.

Saving your baby’s cord blood gives your family the security of being able to take advantage of future advances in stem cell treatments.

Cord Tissue Stem Cells

Cord tissue is the actual umbilical cord and the cells contained within. It is an abundent source of Mesenchymal Stem Cells (MSCs). Learn more about cord tissue.

Cord tissue stem cells, or Mesenchymal Stem Cells (MSCs), are the “building blocks” of the body’s skeletal and connective tissues. They have also shown the ability to differentiate into coronary tissue, hepatic tissue and more.

Cord blood and cord tissue yield two vastly different types of stem cells that can potentially be used to treat different diseases and conditions within the body.

Cord blood stem cells are called Hematopoietic Stem Cells (HSCs). The primary focus in research with HSCs has been on blood and immune system disorders.

The stem cells derived from cord tissue are called Mesenchymal stem cells (MSCs). Researchers have focused their efforts on connective tissue disorders and regenerative medicine with this kind of stem cell.

Saving both cord blood and cord tissue will provide your family with the widest potential scope of treatment options. Learn more.

Cord tissue stem cells (MSCs) represent the most advanced, cutting-edge discoveries in regenerative medicine today.

With over 2,300 MSC clinical trials initiated, scientists predict an explosion of new therapies will emerge, including routine treatments for diabetes, multiple sclerosis, stroke, heart failure, cirrhosis, bone fractures, autoimmune diseases and many more.

MiracleCord uses a process that saves all the different kinds of cells in the umbilical cord tissue. With our process we can consistently recover high percentages of viable stem cells after cryogenic freezing, which mitigates the issues with storing solid tissue.

The issue with storing solid tissue it that there is a cryo-protectant that needs to permeate the cell walls to protect them from crystalizing when frozen, but it can’t effectively do its job when freezing solid tissue because the tissue is so dense. This makes it very difficult to recover any viable stem cells with this method.

MSCs are considered to be immunoprivileged so they can potentially be used to treat an immediate family member with little risk of transplant rejection or GVHD.

No. Currently, there are no public cord blood banks that will collect, process and store MSCs for future transplantation.

Yes. Cord tissue stem cells can be expanded, which multiplies the number of viable stem cells to doses that are suitable for an adult transplant.

Cord Blood Banking

While cord blood stem cells have proven effective in treating many types of cancers, they have also been used to successfully treat many diseases and conditions unrelated to cancer.

A family history of cancer or other diseases may not be known, but families who save their baby’s cord blood understand that these conditions can occur without precedent and without warning.

Studies have shown that cord blood specimens that have been cryogenically preserved for a period of 27 years have the exact same biological composition as they did at the time of their initial preservation.1

All available scientific data suggests that cord blood that is cryogenically stored at the proper temperature should remain viable indefinitely.

1 (September 4, 2023). Retrieved April 19, 2024 from Oxford Academic: Stem Cells Translational Medicine: Abstract 16 Insights into Highly Engraftable Hematopoietic Cells from 27-Year Cryopreserved Umbilical Cord Blood: https://academic.oup.com/stcltm/article/12/Supplement_1/S18/7259695

Yes, because each baby’s cord blood is an exact genetic match for that child and offers the very best chance of survival, with no risk of GVHD, should they need a stem cell transplant in the future.

Also, if a doctor recommends a donor cord blood transplant, siblings are the preferred source.

Lastly, there is approximately a 1-in-4 chance of parents being a match to each child’s cord blood. Storing for multiple children increases the chance of a match being available for parents.

Separate storage is also recommended for multiple births (e.g., twins, triplets), as it maximizes the volume of cord blood collected.

Possibly, but 80% of all publicly donated cord blood samples are not stored for future transplantation so the odds of finding an unrelated HLA match from a public bank are very small.1

When faced with a life-threatening disease or condition, you want to give your family the best chance of survival. Using your baby’s own cord blood stem cells guarantees a perfect genetic match.

When a donor transplant is recommended, siblings are the preferred donor source due to their likelihood of being a suitable HLA match.

Privately banking your baby’s cord blood and cord tissue with MiracleCord ensures that your family will have this valuable resource available for transplant very quickly, without the costly, time-consuming and potentially unsuccessful search that is necessary when looking to a public bank.

1. Parent’s Guide to Cord Blood Foundation. (n.d.). Retrieved 2016-31-May from PGCB: Cord Blood Introduction: Cord Blood Infographic: http://parentsguidecordblood.org/en/cord-blood-infographic

Public banks store unrelated cord blood units from donors. There is no initial cost to the donor; however, retrieving a cord blood unit from a public bank currently costs patients approximately $50,000, and this is often at a time when family finances are already strained.

The unfortunate reality is that 80% of all donated cord blood samples will never be stored for future transplant.2

The chance of finding a donor match from a public bank is very low.

Private banks store cord blood units for your family’s future use. Private cord blood banking ensures that your baby’s cord blood stem cells will be readily available, and will give your family the best chance for survival if a transplant is needed.

1. National Marrow Donor Program. (n.d.). Retrieved 2010-11-January from NMDP: University of Chicago: http://www.marrow.org/PATIENT/Plan_for_Tx/Choosing_a_TC/US_NMDP_Transplant_Centers/Detailed_Center_Information/tc_idx.pl?ctr_id=557
2. Parent’s Guide to Cord Blood Foundation. (n.d.). Retrieved 2016-31-May from PGCB: Cord Blood Introduction: Cord Blood Infographic: http://parentsguidecordblood.org/en/cord-blood-infographic

Yes, 28 states in the U.S. have enacted legislation that either encourages or mandates health care professionals to provide objective information on cord blood banking to expecting parents.

Many of these states have adopted the recommendations that the Institute of Medicine made to Congress in 2005.

Insurance companies typically will not cover the cost of cord blood banking unless you have an immediate family member that is in need of a stem cell transplant at the time that your baby is born.

Please contact your benefits administrator or insurance company for determination.

Though the decision to bank your baby’s cord blood can be made any time before the birth of your baby, planning ahead has many advantages.

Early enrollment ensures that your family has plenty of time to receive your MiracleCord StemCare® thermal collection kit and to review the information provided within.

Since half of all babies are delivered prior to their expected due date, and 12% of all babies are born premature, families who enroll early avoid the risk of missing their only opportunity to bank their baby’s cord blood.

Collection & Processing

Cord blood and cord tissue collection is simple, painless and poses no risk to mother or baby.

After the umbilical cord has been clamped and cut, your doctor or midwife will sanitize a small section of the cord and insert the collection bag needle. The excess blood that had remained in the placenta and umbilical cord after your baby’s birth will flow into the collection bag by gravity. When the flow stops, the collection bag is sealed, labeled and ready for transport to the laboratory.

If you have also chosen to save your baby’s cord tissue, your doctor will then cut a 6 to 8 inch segment of the umbilical cord and place it inside the cord tissue collection container.

A few small vials of the mother’s blood will also be drawn and sent to our laboratory with the cord blood and cord tissue units.

Yes. There is no risk or pain to mother or baby.

The collection process occurs after your baby is born and the umbilical cord has been clamped and cut. It does not interfere with the delivery or care of your newborn.

MiracleCord employs a method of processing cord tissue that saves all cell types, including mesenchymal, endothelial, epithelial, neuronal, hematopoietic and perivascular.

Our method of processing cord tissue consistently yields recovery of high percentages of viable cells after cryopreservation.

Yes, however in order to achieve best results with cord blood banking, it is recommended that you ask your doctor/midwife to limit the delayed cord clamping to a maximum time of 60 seconds after birth. Learn more.

Your MiracleCord StemCare® collection kit includes an FDA approved sterile cord blood collection bag that is safe for use in the sterile field, should you deliver by C-section.

No. MiracleCord’s collection materials are Heparin-free.

The FDA-approved cord blood collection bag used by MiracleCord contains the anticoagulant Citrate Phosphate Dextrose (CDP). Learn more.

MiracleCord’s StemCare® collection kit utilizes an FDA approved, sterile cord blood collection bag that is safe for use in the sterile field should a C-section be necessary.

Your MiracleCord StemCare® thermal collection kit will be sent to you as soon as you enroll.

Click here to Enroll Online, or call 888-743-2673 and our customer service representatives will be happy to assist you.

Any delay in processing your baby’s cord blood and cord tissue can result in a significant loss of viable stem cells.

Studies have shown that cord blood processed within 12 hours of collection yields considerably more viable stem cells than when processed 24 hours after collection.1

Nearly half of the stem cells collected lose their viability when cord blood is processed 24 hours after collection.

Most cord blood banks have a published average time from collection at the hospital to processing at their lab of 24 hours or more.

MiracleCord’s exclusive TimeCritical® cord blood processing provides the unique ability to transport your baby’s cord blood samples to our lab for processing in significantly less time than most other cord blood banks.

1 Shlebak AA, Marley SB, Roberts IAG, Davidson RJ, Goldman JM, Gordon MY. 1999. Optimal timing for processing and cryopreservation of umbilical cord hematopoietic stem cells for clinical transplantation. Bone Marrow Transplantation 23: 131-136.

Shortly after your baby’s cord blood and cord tissue have been collected, call 888-917-7447 to let us know your StemCare® collection kit is ready for pick up.

Our direct medical courier service is available 24/7/365 to retrieve your baby’s specimens from your hospital room and quickly deliver them safely to our laboratory for processing.

Most cord blood banks that advertise the use of a medical courier service will either:

1. Have the medical courier drop-off your baby’s specimens at a FedEx® or UPS® location near your birthing facility, and the conventional shipping company will then handle the transport to their lab, or;

2. Hold the specimens until the next day so a large batch is gathered. The courier will then ship the units as a batch to their laboratory.

Both of these methods used by other cord blood banks are cost-cutting measures that add a considerable delay to the transport time and can result in a significant loss of stem cell viability.

MiracleCord uses a medical courier service that will not transfer custody of your baby’s cord blood and cord tissue to a conventional shipping carrier, and we never use a batch and hold method.

Your collection kit will typically be picked up within 1-2 hours from the time you call to request your pick up. It will then go next flight out directly to our lab facility for processing and cryogenic storage.

FedEx is a registered trademark of Federal Express Corporation; UPS is a registered trademark of United Parcel Service of America, Inc.

No. Cord blood and cord tissue should be kept at room temperature from the time of collection until the time the specimens are processed at our laboratory.

Exposure to high or low temperatures can result in a significant loss of stem cell viability.

The combination of MiracleCord’s specially designed StemCare® collection kit with built-in thermal stabilizers, and our TimeCrital® Processing ensures that your baby’s cord blood and cord tissue will be kept at the appropriate temperature while it is quickly transported from your hospital room to our laboratory.

Yes, we use a multi-compartment cryo-storage bag with five separate segments.

Some doctors charge a small fee for the cord blood and cord tissue collection procedure, which may be covered by your insurance company.

Laboratory

Yes. The laboratory and storage facility are AABB-accredited. This ensures that we adhere to the industry’s most stringent standards for processing and storing cord blood stem cells.

Yes. The laboratory facilities are licensed in all of the lower 48 contiguous United States that require licensing.

Within a few days of your baby’s date of birth MiracleCord will send an email to you confirming your baby’s stem cells have been processed and are safely stored.

Your MiracleCord Certificate of Storage with a comprehensive laboratory report documenting the details of your baby’s cord blood and cord tissue specimens will be available for download approximately 30 days after your baby’s birth.

Yes. The AABB and FDA require several clinical tests to be performed on cord blood, cord tissue and maternal blood at the time of initial processing.

Some cord blood banks forego critical testing procedures that may ultimately limit your family’s ability to use your baby’s stem cells in the future. Without these tests, the FDA may restrict your child’s stem cells from being released and used for transplant.

MiracleCord performs all required testing during initial processing to ensure compliance with AABB standards and FDA guidelines.

MiracleCord can cryogenically ship your baby’s cord blood and cord tissue unit to a transplant facility anywhere in the world when it is needed.

Your baby’s cord blood and cord tissue stem cells can be prepared and ready for shipment very quickly.

When your child’s stem cells are needed for a transplant, please call us at 888-743-2673, and we will guide you through the process.

MiracleCord

MiracleCord is honored to announce that we have received the biotechnology award for Best U.S. Cord Blood Bank of 2021, 2022, 2023, 2024 and 2026 by Global Health & Pharma.

MiracleCord has been providing high-quality cord blood banking services for nearly 20 years.

Choosing MiracleCord means your family will receive unsurpassed quality and exceptional value.

No reputable cord blood banks offer placenta tissue banking. Unfortunately, the banks that are charging for this “service” are taking advantage of unsuspecting consumers.

This is because the stem cells derived from the placenta tissue are identical to those that come from cord tissue.

We have the ability to expand these stem cells by thousands of times, providing a virtually unlimited supply, therefore placental tissue banking provides no additional benefit whatsoever, and it is misleading and unethical for a company to charge customers for this.

Yes. MiracleCord uses a direct medical courier service to transport your baby’s cord blood and cord tissue to our lab facility.

After your collection kit is picked-up by our medical courier partner it will go next flight directly to our lab. Each unit is carefully transported from your hospital room to our laboratory in a temperature-controlled environment by experts trained in the handling of biological tissue.

Our courier will not transfer custody of your baby’s specimens to a commercial shipping carrier such as UPS or FedEx.

MiracleCord includes direct medical courier service with every plan, at no additional cost to you.

MiracleCord provides the highest quality cord blood and cord tissue banking services to families at affordable prices.

MiracleCord plans are all-inclusive with no hidden fees or additional charges.

Click here to view our pricing and payment plan options.

No. You can enroll any time before your baby is born.

Note: Since 50% of all babies are born before their due date and 12% are born premature, it is recommended that you enroll early.

How do I enroll with MiracleCord?

You may enroll online or by phone. It is a simple process that only takes a few minutes.

  • If you wish to enroll online, click here and complete the online form.
  • If you prefer to enroll by phone, please call 888-743-2673 and our Customer Service Professionals will be happy to assist you.

Yes. MiracleCord is a debt-free, profitable, privately held corporation with a long history of fiscal stability.

Client Agreement

MiracleCord, Inc. (“MiracleCord”) is a provider of services for the collecting, testing, processing, cryopreserving and storing of cells collected from a newborn’s umbilical cord blood (“Cord Blood”) as well as certain umbilical cord tissue (“Cord Tissue”), (individually a “Neonatal Specimen” or collectively “Neonatal Specimens”). This Client Agreement (“Agreement”) explains MiracleCord’s obligations to you (“Client”) and your agreements with MiracleCord, and to ensure, where applicable, that where there is a birth mother other than Client (e.g., a surrogate, gestational carrier or birth mother placing a baby for adoption – referred to herein as a “Birth Mother”) consents to the terms of this Agreement and the obligations that may then reside with the Birth Mother per the Agreement.

MiracleCord’s Obligations
1. MiracleCord shall provide to the Client (or to the Birth Mother, when applicable) a collection kit for the Client or Birth Mother to bring to the hospital or other birth location for the collection of the Client’s newborn baby’s Cord Blood and/or Cord Tissue, and a maternal blood sample (collectively “Specimens”). MiracleCord shall include with the collection kit reasonable directions for the attending medical professional for the use of the kit and the collection of the Neonatal Specimens.
2. As soon as possible after the Specimens have been collected, the Client (or the Birth Mother, when applicable) will contact MiracleCord’s medical courier partner (“Courier”) to request pick up. The Courier will pick up the Specimens at the birth location and deliver them to MiracleCord’s laboratory partner (“Lab”).
3. Upon arrival at the Lab certain tests will be conducted on the Specimens.
4. The Neonatal Specimens will be uniquely identified, stored, and maintained at a cryogenic storage facility, and shall remain in cryopreserved storage for the full period of the Agreement between MiracleCord and Client or until the Agreement is terminated as provided for in this Agreement.
5. MiracleCord reserves the right to transfer the Neonatal Specimens, at its cost, during the term of this Agreement.
6. Upon receipt by MiracleCord of a written request from the Client, MiracleCord shall arrange for some or all of the Neonatal Specimens (as requested by the Client) to be transported directly to a physician appropriately qualified to perform a transplant or medical procedure (“Physician”), or to a medical care facility, to be used in a medical procedure as determined by Client and Client’s physician, subject to FDA guidelines. Except as otherwise provided in this Agreement, MiracleCord shall not transport the Neonatal Specimens from the storage facility to any party, including Client, other than to a physician or medical care facility for a medical procedure. The initial transportation within the United States of the Neonatal Specimen(s) as provided herein shall be at MiracleCord’s expense. A subsequent transportation of the Neonatal Specimen(s) within the United States, or the transportation of the Neonatal Specimen(s) outside of the United States shall be at Client’s expense.
7. Upon termination of this Agreement for storage of the Neonatal Specimens between MiracleCord and the Client, MiracleCord will transport, at Client’s cost, the Neonatal Specimens to a physician, medical care facility or appropriately accredited or licensed cryopreservation laboratory/storage facility, as directed by Client and subject to all applicable laws and regulations. Such direction shall be in the form of a document provided to Client that shall be executed, notarized and returned to MiracleCord. Alternatively, at Client’s direction (in accordance with the preceding), or if no direction is provided by Client within sixty (60) days after termination, MiracleCord or the Lab will dispose of the Specimens in an appropriate manner, including but not limited to transfer to a research facility.

Client’s Obligations
1. The Client will carefully read and execute this Agreement and ensure the Client (and Birth Mother, where applicable) has completed the Health History Profile and the “Parent” section of the Collection Worksheet provided by MiracleCord. The Client is encouraged to have the documentation related to the collection, testing, processing and storage of the Specimens reviewed by Client’s counsel and medical professional of Client’s choosing.
2. As provided for in this Agreement and for avoidance of any doubt, if the Client executing this Agreement is not the Birth Mother of the child whose Neonatal Specimens are being collected, the Client will obtain the written consent of the Birth Mother to all of the applicable terms and conditions in this Agreement by having her sign this Agreement.
3. The Client will select the medical facility and medical professional that will conduct the collection of the Neonatal Specimens. The Client acknowledges the selection of the medical facility and the medical professional is solely the responsibility of the Client and that MiracleCord does not select or otherwise determine who shall perform these services.
4. Client agrees to notify the medical professional and the medical facility staff of the desire to collect the baby’s Cord Blood (and Cord Tissue if applicable).
5. As soon as possible after collection of the Specimens, the Client or Birth Mother will call the Courier to request pick up of the Specimens for delivery to the Lab.
6. If the checkbox in the top section of the “Parent” section on the Collection Worksheet is not checked and the baby’s cord tissue sample arrives at the Lab, it will be processed and stored, and the Client will be billed for the applicable cord tissue fees.
7. The Client will make all payments in a timely manner.

Fees and Plans
1. At the time of initial enrollment of the Client to receive MiracleCord’s services, the Client will pay a non-refundable deposit of $200.00 (in the event of multiple births, the deposit will be $200.00 per baby). Upon collection of the Specimens, Client shall be obligated for the payment of the balance of the fees for the plan as selected by the Client. By accepting this Agreement, if the Client elects a financing arrangement for the fees, Client hereby accepts the Payment Plan Disclosure provided to Client via email, or if not provided by email, then on the MiracleCord website. Other terms and conditions may apply. Acceptance of the Client Agreement, including all of the terms and conditions herein, shall occur upon either (i) execution of this Agreement or (ii) payment of the non-refundable $200 deposit.
2. Upon accepting this Agreement, the Client will select one of the storage and payment plans that is on MiracleCord’s website for online enrollment. Storage plan options include an annual plan and long-term plan(s).
3. The annual plans include: (a) a separate fee for the initial service, which includes testing and processing of the Specimens, the transport of Specimens by the Courier to the Lab, and the collection kit for the Specimens, and (b) the storage fee for the first twelve months. Thereafter, the Client will be invoiced for additional annual storage fees. Annual storage fees will be charged automatically to the credit/debit card on file approximately fourteen (14) days before your baby’s birthday, unless you have chosen a long-term storage plan. Annual storage plan fees may be adjusted from time to time.
4. The long-term plans include: (a) a separate fee for the initial service, which includes testing and processing of the Specimens, the transport of Specimens by the Courier to the Lab, and the collection kit for the Specimens, and (b) the applicable storage fee for the period set forth in the specific long-term plan selected by the Client.
5. The Client will be charged a late fee equal to 10% of the amount due if any required fee is not paid when due. Additionally, any amount not paid within thirty (30) days of the date due shall accrue interest at the rate of 1.5% per month until paid.
6. As set forth above, there is no MiracleCord fee for an initial transfer of the Neonatal Specimen(s) that is retrieved by the Client to be used in an engrafting or transplant procedure within the United States. MiracleCord shall be responsible for any shipping or courier costs for an initial transfer of the Neonatal Specimen(s) for use in such medical procedure within the United States. The Client shall be responsible for any shipping or courier costs for any subsequent transfer of Neonatal Specimen(s), or for any transfer to any location outside of the United States. The fee to transfer the Neonatal Specimen(s) that is retrieved by the Client for any reason other than an engrafting or transplant procedure will be made available to Client by MiracleCord by contacting MiracleCord prior to requesting retrieval of the Neonatal Specimens.

Limitations of the Program
1. MiracleCord shall have no liability in the event of:
a. Failure of the medical professional to correctly collect, label or assemble the Specimens inside the collection kit;
b. Failure of the medical professional to attend to any medical issue that arises during the delivery of the newborn, even if such failure was due to such medical professional’s attention to collecting the Specimens;
c. Failure of the Courier to deliver the Specimens, due to loss or destruction of the Specimens while in the Courier’s possession;
d. Any contamination of the Specimens at the time of collection and up until the Specimens are delivered to the laboratory for further processing and testing;
e. Any event that harms or contaminates the Specimens that was beyond the reasonable control of MiracleCord, such as, fire, explosions, power outages, storms, floods, terrorism, wars, labor disputes, governmental action, imposition of statutes, laws or regulations that materially alter the program for collection, processing, testing and storage of the Specimens;
f. Any failure of an engrafting procedure or transplant of the Neonatal Specimens, except as provided in MiracleCord’s Quality Guarantee with respect to Cord Blood.
2. MiracleCord’s liability to the Client for any claims, loss, harm, damages, expenses, costs (including attorneys’ fees) shall be limited to a return of the fees paid by Client for MiracleCord’s services under this Agreement.
3. In the unlikely event a Neonatal Specimen is reasonably determined to be inappropriate for the program, MiracleCord will return to Client any storage fees paid by Client in advance, whether under any annual or long-term plan.
4. MiracleCord shall have no liability for, and Client hereby releases and discharges MiracleCord from any obligations with respect to, any disclosure of information in accordance with the Privacy Policy that is attached to this Agreement and/or provided on MiracleCord’s website.

Quality Guarantee
As a MiracleCord client, the viability of your baby’s umbilical cord blood stem cells is guaranteed by MiracleCord with respect to the initial stem cell transplant procedure. If, in an initial stem cell transplant procedure, your child’s Cord Blood stem cells fail to engraft, MiracleCord will pay up to one hundred thousand dollars ($100,000) toward the cost of procurement of an alternative stem cell source, if medically indicated. Cord Tissue is specifically excluded from the terms of this quality guarantee.
1. Definition of Engraftment – Stem cell engraftment is defined as three consecutive days in which the patient’s absolute neutrophil count is at least 500 per microliter, with the first of the three measurements occurring within 100 days of transplantation.
2. Quality Guarantee Medical Requirements:
a. The Cord Blood must have been collected with a MiracleCord collection kit and processed and cryogenically stored by the Lab, and cannot subsequently have been transferred to a storage facility other than a MiracleCord Lab;
b. The results of the testing by the Lab of the Cord Blood and maternal blood must show no evidence of infection or contamination;
c. The cells must be used in a stem cell transplant for hematopoietic reconstitution either by the donor (autologous) or by the donor’s biological parents or biological siblings;
d. The donor cells must be at least a 4 out of 6 HLA match to the recipient;
e. The Cord Blood unit must contain at least 2 x 107 total nucleated cells (TNC) per kilogram weight of recipient;
f. The Cord Blood unit must contain at least 1 x 105 CD34+ cells per kilogram weight of recipient;
g. The transplant facility must use a validated cord blood thawing procedure, and the cord blood stem cells must be administered immediately upon thawing;
h. The stem cells must be administered to the transplant recipient by a transplant physician, in a medical facility qualified by an Institutional Review Board (IRB) for stem cell transplantation;
i. The cells must not be subjected to manipulation, cell expansion, positive or negative cell selection, or gene therapy;
j. The patient must be given sufficient time (post-transplant) for engraftment to occur;
k. The stem cells must not be used in combination with supplemental stem cell sources, including, but not limited to, additional cord blood, peripheral blood, or bone marrow;
l. The stem cells must not be used in experimental procedures, including, but not limited to, mini-transplants, or other types of extensive and/or experimental laboratory cultures;
m. The stem cells and/or transplant recipient must not be subjected to an investigational drug within 100 days of transplantation.
3. Quality Guarantee Documentation Requirements:
a. Signed statement from the transplant physician attesting that engraftment did not occur;
b. Medical records documenting proof of non-engraftment;
c. Proof that all third-party payers responsible for payment of any fees associated with the collection, storage, or transplant of the Cord Blood have been notified of the existence of MiracleCord’s Quality Guarantee and the amount to be paid.
4. This Quality Guarantee is not available to:
a. Clients that reside in areas where this guarantee is prohibited by law, or in the event the transplant procedure is performed outside of the United States;
b. Clients whose cord blood banking fees or transplant fees are paid in full or in part by Medicare or Medicaid;
c. Clients whose cord blood banking fees (i) are paid in part or whole by third-party payers in Massachusetts and Michigan or (ii) have been waived or forgiven, in whole or in part, by MiracleCord prior to the request by the Client for transplant of the stem cells;
d. Clients who have an unpaid balance due to MiracleCord for services rendered;
e. Clients enrolled in MiracleCord’s Select Transplant Program.
f. Clients who have directed a transfer of the Neonatal Specimens to any location other than to a Physician or medical care facility for use in a transplant or medical procedure.
5. Your baby’s Cord Blood is not guaranteed to be a match for a family member, and an umbilical cord blood transplant may not provide the best course of treatment for any particular disease. Ultimately, the use of your child’s cord blood stem cells will depend on the physician’s determination of disease type and the HLA matching for donor and recipient.

Informed Consent
1. To confirm that the Client (a) understands the services to be provided by MiracleCord, and (b) has been informed of the processes and procedures that will be performed by MiracleCord or the Lab, the following provisions regarding the Client’s informed consent for such engagement and receipt of services is incorporated into this Agreement. The term “I”, as used in this informed consent provision, is a reference to the Client and, where different from the Client, the Birth Mother:

I acknowledge that I have decided and consented to have my baby’s Cord Blood and/or Cord Tissue (as applicable) collected after the birth of my baby and to have such Neonatal Specimens tested, processed, cryopreserved and stored. I also agree to provide samples of my own blood for testing. Although infrequent, I understand that at the time of childbirth complications may occur and attending to my health or the health of my newborn is the priority; therefore, it may not be possible to collect my baby’s Neonatal Specimens.

I acknowledge that it is my decision to select the medical professional that will attend to the birth of my baby and conduct related medical procedures, including the collection of my baby’s Neonatal Specimens. I understand that MiracleCord may contact the medical professional for the purposes of discussing MiracleCord’s services, and in certain cases, such medical professional may receive payment from MiracleCord for performing services related to the collection of my Specimens. In order to ensure and enhance the communications for my benefit between the hospital, medical professional and MiracleCord, I hereby authorize the hospital and medical professional to disclose my protected health information related to the collection of my Specimens with MiracleCord. MiracleCord may provide the hospital and medical professional with a copy of this authorization. I understand that I am entitled to be provided a copy of any disclosed information and that this authorization can be revoked at any time. I understand that MiracleCord will not use my protected health information for marketing or promotional purposes.

I understand that the Lab will perform tests on the Cord Blood, including cell viability, total nucleated cell count, CD34+, bacteria and fungus to determine the nature and quality of the Cord Blood, and the Lab will perform tests on the Cord Tissue (if collected), including cell viability and sterility, to determine the nature and quality of the Cord Tissue, and that my blood will be tested for certain infectious diseases including human immunodeficiency virus (HIV), hepatitis B and hepatitis C viruses, human T-lymphotrophic virus (HTLV), cytomegalovirus (CMV), and syphilis. I understand that if applicable law, regulations, certification requirements or industry standards are modified or amended, then alternative, additional or substitute tests may be performed. I acknowledge and consent to MiracleCord and the Lab making such reports of the results of these tests as required by applicable law.

I understand that MiracleCord may elect not to retain the collected Neonatal Specimens if, in MiracleCord’s reasonable judgment such Neonatal Specimen is not appropriate for storage. Such reasons may include, but are not limited to, if there is any condition that may affect the viability of the future use of such Neonatal Specimen. The final decision as to whether such Neonatal Specimen is appropriate for storage shall be that of MiracleCord and the Lab. I understand that I will be notified in writing of a decision that such Neonatal Specimen is not appropriate for either testing or storage, and such a determination shall result in the termination of any further obligations of either party under this Agreement.

I understand that there are potential benefits of Cord Blood and Cord Tissue for use in the treatment of certain diseases and conditions. I also understand that the limits of the longevity of storing Neonatal Specimens are not completely known. I acknowledge that it is not possible to know if transplanting Cord Blood or Cord Tissue stem cells will be effective in the treatment of any particular diseases or conditions. I understand that the Neonatal Specimens are a perfect match for my baby, and have been informed that, unless and until further testing is completed, it is not possible to know whether the Neonatal Specimens will be a match for any other particular individual. I understand that the collection of Specimens, and transplantation of Neonatal Specimens are medical procedures, and that there are inherent risks in any medical procedure. I acknowledge that MiracleCord does not and will not, perform, advise, or participate in any way in such medical procedures and will not have any liability for such medical procedures, and I release and discharge MiracleCord from any such liabilities.

Miscellaneous
1. Confidentiality – MiracleCord acknowledges the confidential nature of the Client’s information provided to MiracleCord (and the information about the Client’s child) and will use its reasonable best efforts to maintain the confidentiality of such information, except as may be required by applicable law. The Client agrees to the release of information by MiracleCord to any medical facility, hospital, laboratory or medical professional providing services to the Client that are related to the Specimens, including the provision of any engrafting or transplant procedures.
2. Termination by Client – This Agreement may be terminated by the Client (a) at any time prior to collection of the Specimens, or (b) after giving MiracleCord at least sixty (60) days prior written notice at any time after storage of the Neonatal Specimens. All fees paid through the date of termination are non-refundable.
3. Termination by MiracleCord – This Agreement may be terminated by MiracleCord (a) if MiracleCord has determined any such Neonatal Specimen is not appropriate for storage, in which case MiracleCord will return to Client any storage fees paid by Client in advance for such Neonatal Specimen, whether under any annual or long-term plan, (b) if Client does not timely pay any fee when due, or (c) at any time after giving Client at least sixty (60) days prior written notice of such termination, in which case MiracleCord will return to Client a pro rata portion of any storage fees paid in advance under any annual or long-term plan.
4. Upon termination of this Agreement by Client in accordance with Section 2 above, or by MiracleCord in accordance with Sections 3(a) or 3(c) above, and after storage has commenced, Client may request to retrieve the Neonatal Specimen and shall pay the applicable retrieval fee at such time. If either (a) pursuant to the preceding sentence, Client does not request retrieval of the Neonatal Specimen or (b) MiracleCord has terminated the Agreement in accordance with Section 3(b) above, MiracleCord, without liability, shall be free to use or dispose of such Neonatal Specimen in an appropriate manner, including but not limited to transfer to a public cord blood or tissue bank or to a research facility. Client hereby releases and discharges MiracleCord from any and all claims, liabilities, costs or actions that may arise out of or result from MiracleCord’s activity or handling of the Specimens after termination. In addition to the foregoing, MiracleCord shall be entitled to recover from Client all costs and fees (including reasonable attorney’s fees) incurred in any action to collect any amounts due from Client under this Agreement.
5. Consent to Communications – Client understands and agrees that MiracleCord and Client communications may occur in several different ways and means of communication. Client agrees that MiracleCord may communicate with Client by means of any of email, text messaging, telephone, or written communication. Client has the right to opt out of such communications by using that means of communication you wish to stop at any time: (i) an email to MiracleCord at [email protected]; (ii) a text “STOP” in response to a MiracleCord text; (iii) a call to MiracleCord customer services at 1-888-743-2673 or (iv) by letter to MiracleCord at 875 N Michigan Ave, Ste 3100, Chicago, IL 60611.
6. Notices – Any notice either required or permitted under this Agreement may be given (a) personally to the other party, (b) by private delivery services (e.g., Federal Express or UPS) with a return receipt requested, or (c) by United States registered or certified mail return receipt requested. Notice shall be sent to the other party at their last known address.
7. Dispute Resolution – In the event of any dispute between the Client (or Birth Mother where applicable) and MiracleCord with respect to this Agreement or related in any way to the collection, testing, processing and storage of the Specimens, or a dispute over any payments or fees, such dispute will be submitted to binding arbitration under the rules of the American Arbitration Association (the “AAA Rules”). The arbitration will be held in Chicago, Illinois before a single arbitrator. The fees of the arbitrator will be shared equally by the parties. Other than such arbitrator fees, the prevailing party in such arbitration, as determined by the arbitrator will be entitled to recover its costs and expenses of the arbitration. The arbitrator will issue a written opinion of his/her decision, and such decision will be binding, final and enforceable in any court of competent jurisdiction.
8. Governing Law – This Agreement and the relationship between the Client, the Birth Mother and MiracleCord shall be governed by and interpreted in accordance with the laws of the State of Illinois without regard to its choice of laws rules.
9. Assignment – Upon the attainment of the age of majority by the child from whom the Neonatal Specimens were collected (the age of majority as determined in the state of the domicile of the child, but in no event earlier than the age of majority in the State of Illinois), the Agreement between the Client and MiracleCord shall be assigned to such child who shall then be the Client hereunder. Additionally, if different from the initial Client, this Agreement shall be assigned to any guardian of the child from whom the Neonatal Specimens were collected. MiracleCord may assign its rights and obligations under this Agreement (i) to any acquirer of the majority of the stock of MiracleCord or substantially all of the assets of MiracleCord or (ii) in the unlikely event that, for any reason, MiracleCord ceases to be an ongoing concern, to ensure the uninterrupted provision of services, MiracleCord may assign its rights and obligations under this Agreement to the Lab. Except for the foregoing circumstances, neither the Client nor MiracleCord shall assign its rights and obligations under this Agreement without the prior written consent of the other party. All of the terms and conditions shall be binding on any successor or assign of a party.
10. Waiver – No waiver by any party with respect to any breach or default or of any right or remedy, and no course of dealing, shall be deemed to constitute a continuing waiver of any other breach or default or of any other right or remedy, unless such waiver is expressed in writing signed by the party to be bound by such waiver. Failure of a party to exercise any right, under this Agreement or at law or in equity, shall not be deemed a waiver of such right or rights in the future.
11. Severability – If any of these terms and conditions are held to be invalid or unenforceable, such invalidity or unenforceability will not affect the other terms and conditions, which will remain in full force and effect.
12. Entire Agreement – This Agreement, and the attachments to this Agreement, represent the entire agreement between the Client and MiracleCord and supersede any oral or written prior agreements, representations, or understandings.

The Client (and the Birth Mother, if different than the Client, and solely with regard to those provisions of this Agreement that are applicable to the Birth Mother) has indicated acceptance of this Agreement as of the date set forth below.

Client                                                                Birth Mother

__________________________________             __________________________________
Printed Name                                                    Printed Name

__________________________________             __________________________________
Signature                                     Date              Signature                                     Date

CLIENT RIGHTS
Medical care for the birth mother and baby is of the highest priority to MiracleCord. If the medical condition of the mother or baby becomes a concern, the collection process should be withdrawn. Under no circumstances should the collection process be completed if any medical care would be sacrificed to the mother or baby. The Client’s healthcare professional is responsible for identifying any circumstances that would put the mother or baby at risk. The Client also has the right to deny consent of the collection at any time without affecting access to medical care. Also, the Client has the right to have any and all questions answered concerning any part of the process, completion of the forms, testing for infectious diseases, and storage (this list is not all-inclusive).

PRIVACY POLICY
MiracleCord takes seriously its obligation to keep all personal and health information strictly confidential and to limit the disclosure of such information. Please read our Privacy Policy for more information.

CA0526.1

Privacy Policy

MiracleCord is committed to keeping the personal and health information you provide to us strictly confidential and to limit the disclosure of such information.

The Information

As a result of your enrollment as a Client of MiracleCord, you will be providing MiracleCord with various types of information. You will provide MiracleCord with personal identification information such as names, addresses, phone numbers and credit card numbers. You will also provide MiracleCord with a medical health history questionnaire that contains information about you. Included in “information” that is subject to this policy is any additional information you voluntarily provide to us.

You understand and agree that as a result of your use of this site and interest in MiracleCord that MiracleCord may communicate with you by means of any of email, text messaging, telephone or written communication. You have the right to opt out of such communications by using that means of communication you wish to stop at any time: (i) an email to MiracleCord at [email protected]; (ii) a text “STOP” in response to a MiracleCord text; (iii) a call to MiracleCord customer service at 1-888-743-2673; or (iv) by letter to MiracleCord at 875 N Michigan Ave, Ste 3100, Chicago, IL 60611.

MiracleCord’s Obligations of Confidentiality

With respect to the personal identification information you provide to us, MiracleCord will only disclose such information to its employees, agents, representatives and its service partners providing collection, testing and storage services related to the Specimens, and only where such individuals or entities have demonstrated a need to know for the purposes of completing the process of storing the Specimens as part of the program in which you have enrolled, and maintaining adequate records related to such storage. Without your consent, MiracleCord will not share or sell your information to any vendor, marketing or promotion firm or any other third party. One exception to this general commitment is that MiracleCord will comply with all applicable governmental orders or requirements as well as any judicial or other regulatory agency subpoenas. MiracleCord will notify you in the event it receives such order, requirement or subpoena.

With respect to the medical information you provide to MiracleCord, including your responses on the medical health history questionnaire and the results of any tests on the Specimens, MiracleCord will only disclose such information as required by applicable federal or state law. Additionally, MiracleCord may disclose such information to a third party for whom you have granted consent for such disclosure, including any medical professional providing health care services to you, your child or any third party. Any information related to the Specimens maintained by either MiracleCord or its service partners will be treated the same as medical information as described under this policy.